Full View

Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer

Y Ogura, N Kataoka, Y Kunimatsu… - Thoracic …, 2021 - Wiley Online Library
Background First‐line chemoimmunotherapy (CIT) has improved overall survival (OS) and
progression‐free survival (PFS) outcomes among patients with non‐small cell lung cancer …
被引用次数：22 相关文章

Predictors of survival among Japanese patients receiving first-line chemoimmunotherapy for advanced non-small cell lung cancer

Y Ogura, N Kataoka, Y Kunimatsu… - Thoracic …, 2021 - pubmed.ncbi.nlm.nih.gov
Background First-line chemoimmunotherapy (CIT) has improved overall survival (OS) and
progression-free survival (PFS) outcomes among patients with non-small cell lung cancer …

Predictors of survival among Japanese patients receiving first-line chemoimmunotherapy for advanced non-small cell lung cancer.

Y Ogura, N Kataoka, Y Kunimatsu, Y Tachibana… - Thoracic …, 2020 - europepmc.org
Background First-line chemoimmunotherapy (CIT) has improved overall survival (OS) and
progression-free survival (PFS) outcomes among patients with non-small cell lung cancer …
[HTML] nih.gov

[HTML][HTML] Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer

Y Ogura, N Kataoka, Y Kunimatsu, Y Tachibana… - Thoracic …, 2021 - ncbi.nlm.nih.gov
Background First‐line chemoimmunotherapy (CIT) has improved overall survival (OS) and
progression‐free survival (PFS) outcomes among patients with non‐small cell lung cancer …

Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer

Y Ogura, N Kataoka, Y Kunimatsu… - Thoracic …, 2021 - search.proquest.com
Background First‐line chemoimmunotherapy (CIT) has improved overall survival (OS) and
progression‐free survival (PFS) outcomes among patients with non‐small cell lung cancer …